Red flags have gone up regarding the vast overreach of Speaker Pelosi’s sweeping bill (H.R. 3), raising concerns that its key provisions that would enable the government to dictate prescription drug prices may be deemed unconstitutional.
In this first of a series of articles dedicated to the Women in Bio Boardroom Ready program, we discuss what the program entails and feedback from some previous participants.
Life sciences companies seeking to raise capital or form early partnerships with strategic players often make avoidable mistakes. Here are some tips that can increase your probability of a successful transaction.
What can make a company decide to enter new therapeutic entities into clinical development after decades as a dedicated supplier to bio research labs? Here we explain the reasons and implications of ArunA Bio’s decision.
When both members of a dual-career couple are in senior leadership roles, the challenges are intense. How couples face those challenges has consequences for their teams and organizations as well as for themselves and families.
Rob Wright explores what makes a serial entrepreneur tick (part 1) via Brad Margus, cofounder and CEO of Cerevance. Margus may have started out in the shrimping business, but he went on to found a disease specific 501c3 nonprofit, ultimately leading him to found three different biopharmaceutical companies.
In part 2 of what makes serial entrepreneur Brad Margus tick, Rob Wright explores the various lessons learned by Margus during the founding of multiple biopharmaceutical companies, along with an update on the 501c3 nonprofit organization he helped to cofound, the A-T Children’s Project.
John Oyler, cofounder and CEO of BeiGene, a 9-year-old global biopharmaceutical company today valued at more than $8.5 billion, discusses the importance of having a “rock star” scientist cofounder in Xiandong Wang, Ph.D., and his impact on recruiting top talent.
